MCVEF Quote, Financials, Valuation and Earnings

BioInvent International AB has a net margin of 2.83% compared to Medicover AB's net margin of -4171.4%. Medicover AB's return on equity of 14.26% beat BioInvent International AB's return on equity of -45.16%.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than BioInvent International AB, analysts believe Medicover AB is more attractive than BioInvent International AB.

Medicover AB has a beta of 0.142, which suggesting that the stock is 85.802% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.984%.

Medicover AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0.62%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 129.44% of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $712M, which are larger than BioInvent International AB quarterly revenues of $320.6K. Medicover AB's net income of $20.1M is higher than BioInvent International AB's net income of -$13.4M. Notably, Medicover AB's price-to-earnings ratio is 47.04x while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.53x versus 9.32x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.

BioArctic AB has a net margin of 2.83% compared to Medicover AB's net margin of -4.8%. Medicover AB's return on equity of 14.26% beat BioArctic AB's return on equity of 52.54%.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than BioArctic AB, analysts believe Medicover AB is more attractive than BioArctic AB.

Medicover AB has a beta of 0.142, which suggesting that the stock is 85.802% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medicover AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0.62%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 129.44% of its earnings as a dividend. BioArctic AB pays out 17.32% of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Medicover AB's is not.

Medicover AB quarterly revenues are $712M, which are larger than BioArctic AB quarterly revenues of $19.6M. Medicover AB's net income of $20.1M is higher than BioArctic AB's net income of -$938.5K. Notably, Medicover AB's price-to-earnings ratio is 47.04x while BioArctic AB's PE ratio is 30.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.53x versus 14.99x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of 2.83% compared to Medicover AB's net margin of 21.72%. Medicover AB's return on equity of 14.26% beat Camurus AB's return on equity of 19.19%.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than Camurus AB, analysts believe Medicover AB is more attractive than Camurus AB.

Medicover AB has a beta of 0.142, which suggesting that the stock is 85.802% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.17%.

Medicover AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0.62%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 129.44% of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $712M, which are larger than Camurus AB quarterly revenues of $49.4M. Medicover AB's net income of $20.1M is higher than Camurus AB's net income of $10.7M. Notably, Medicover AB's price-to-earnings ratio is 47.04x while Camurus AB's PE ratio is 44.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.53x versus 14.30x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 2.83% compared to Medicover AB's net margin of -217.19%. Medicover AB's return on equity of 14.26% beat Hansa Biopharma AB's return on equity of --.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than Hansa Biopharma AB, analysts believe Medicover AB is more attractive than Hansa Biopharma AB.

Medicover AB has a beta of 0.142, which suggesting that the stock is 85.802% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.963%.

Medicover AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0.62%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 129.44% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $712M, which are larger than Hansa Biopharma AB quarterly revenues of $8.1M. Medicover AB's net income of $20.1M is higher than Hansa Biopharma AB's net income of -$17.5M. Notably, Medicover AB's price-to-earnings ratio is 47.04x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.53x versus 10.42x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.